IGF-1 LR3 Dosage Guide: Protocols, Calculator & Safety

Conservative beginner protocol:

• Dose: 20 mcg subcutaneous
• Frequency: Once daily (either morning or post-workout)
• Timing: With 30-40g fast-digesting carbohydrate within 30 minutes of injection
• Duration: 4 weeks initial cycle with blood glucose monitoring

Do not skip the carbohydrate: This is the most important rule. IGF-1 LR3's insulin-receptor cross-reactivity will drop blood glucose in the post-injection window. Users who inject fasted or combined with carb restriction have experienced hypoglycemic episodes requiring emergency intervention. Plan a carbohydrate-containing meal or shake to coincide with injection timing.

Reconstitution: IGF-1 LR3 typically ships as 1 mg lyophilized powder. Reconstitute with acetic acid-stabilized solution or BAC water as supplier instructs (IGF-1 LR3 is unusual in often requiring dilute acetic acid rather than BAC water — verify with your source):

• 1 mg + 1 mL = 1 mg/mL concentration
• 20 mcg = 0.02 mL = 2 units on U-100 insulin syringe (very small volume)

Many users dilute further for ease of accurate measurement:

• 1 mg + 2 mL = 500 mcg/mL
• 20 mcg = 0.04 mL = 4 units

Timing considerations:

Option A — Morning with breakfast: Inject 20 mcg upon waking; consume high-carb breakfast within 30 min. Simplest and safest for beginners.

Option B — Post-workout with carb/protein shake: Inject 20 mcg immediately post-training; consume carb + protein shake with 30-40g carbs within 20 min. Theoretically aligns IGF-1 signal with muscle damage window.

Option C — Pre-workout: Not recommended for beginners — the hypoglycemia risk during training is significant.

First-dose precautions:

• Have simple carbohydrate (juice, glucose tabs) immediately available
• Test blood glucose 30, 60, 90 min post-injection for the first 3-5 doses
• Have a diabetes-literate friend or partner aware of what you're doing
• If you develop shakiness, sweating, or confusion, immediately consume fast-digesting carbohydrate

Labs to run before starting:

• Baseline IGF-1 (to see where you are relative to age-adjusted norms)
• Fasting insulin, fasting glucose, HbA1c
• Comprehensive metabolic panel
• CBC (baseline hematologic values)
• Abdominal imaging is reasonable but not strictly required for short-term use

Who should not start:

• Users with any active or suspected malignancy
• Strong family history of hormonally-responsive cancers
• Uncontrolled diabetes
• Hypoglycemia unawareness
• Pediatric or adolescent users (use is highly inappropriate without specialist supervision)
• Users who will not commit to glucose testing and carbohydrate management

Standard intermediate protocol:

• Dose: 30-50 mcg subcutaneous
• Frequency: Once daily
• Timing: Post-workout on training days, morning with breakfast on rest days
• Cycle: 4-6 weeks on / 2-4 weeks off

Why cycling: IGF-1 LR3 is not cycled primarily for receptor desensitization (IGF1R does not desensitize rapidly at these doses) but rather to:

• Limit cumulative peripheral tissue growth (gut, organs)
• Limit cumulative cancer-promotion mechanistic exposure
• Re-establish hypoglycemia tolerance

Dosing optimization:

Site-targeted injection (local anabolic effect): Some intermediate users inject IGF-1 LR3 directly into trained muscle groups immediately post-workout (bilateral 10-20 mcg into each side of the trained muscle, typically chest, back, or legs). Rationale: high local tissue concentration drives targeted hypertrophy. Evidence: primarily anecdotal; mechanistically plausible but not validated in controlled trials. Risks: increased hypoglycemia from pooled peripheral injection, increased injection site soreness/inflammation.

Systemic SC injection (standard): Single SC injection in abdomen or thigh; drives systemic IGF-1 elevation affecting all IGF1R-expressing tissues. Simpler, safer than multiple IM injections.

Combination with exogenous insulin (not recommended):

Some advanced bodybuilders combine IGF-1 LR3 with rapid-acting insulin post-workout for maximum glucose disposal and nutrient partitioning. This combination is extremely dangerous — both agents independently drive hypoglycemia; combined, the risk of severe hypoglycemia requiring emergency intervention is high. If undertaken at all, only with continuous glucose monitoring and extensive carbohydrate protocols. Most experienced practitioners specifically warn against this combination.

Cycling protocol example:

• Weeks 1-4: 40 mcg SC daily, post-workout or morning
• Weeks 5-8: Off (body composition assessment, labs)
• Weeks 9-12: 50 mcg SC daily
• Weeks 13-16: Off
• Continue cycling pattern

Monitoring during cycle:

• Weekly fasting glucose (ensure no creeping elevation despite exogenous IGF-1)
• Weekly fasting insulin
• Week 4 and week 8: IGF-1, CBC, CMP
• Quarterly: Abdominal palpation for any unusual masses; consider abdominal imaging annually

Advanced protocol — only for experienced users with full risk awareness:

The advanced IGF-1 LR3 user is generally combining it with other anabolic strategies in pursuit of maximum physique goals:

Anabolic intensification stack:

• IGF-1 LR3: 50-80 mcg SC post-workout, cycled 4-6 weeks on / 4 weeks off
• Testosterone replacement or cycle (if applicable)
• GHRH + GHS combination for pituitary GH axis support (sermorelin + ipamorelin, or CJC-1295 + ipamorelin)
• BPC-157 + TB-500 for connective tissue and recovery
• Disciplined nutrition with periworkout carbohydrate planning and overall caloric surplus

Why stack with GH axis support:

Endogenous GH/IGF-1 operates at physiologic levels with proper IGFBP regulation. Supplementing only exogenous LR3 bypasses the IGFBP system and produces all its effects through the unbound (free) IGF-1 mechanism. Some practitioners stack with GHRH/GHS compounds to also drive native IGF-1 production, arguing the combination gives you "best of both worlds." The counterargument is that you're stacking mechanisms and compounding the theoretical cancer-risk signal.

Cycling considerations for advanced use:

• Never exceed 8 consecutive weeks of IGF-1 LR3 use
• Ensure 2-4 week washout between cycles minimum
• Annual comprehensive physical with abdominal imaging
• Semi-annual IGF-1 monitoring with trend analysis
• Annual colonoscopy after age 40 (or earlier with family history)

Site-targeted protocols (experienced only):

Some bodybuilders inject small doses directly into trained muscle for local anabolic effect:

• 10-20 mcg per side, bilateral injection, immediately post-training
• High local tissue concentration drives targeted hypertrophy (theoretical)
• Increases total IGF-1 exposure per session compared to single SC dose

Combinations to avoid at advanced level:

• IGF-1 LR3 + exogenous insulin: Compounded hypoglycemia risk; potentially lethal
• IGF-1 LR3 + mecasermin (Increlex): Redundant; both are IGF1R agonists
• IGF-1 LR3 + sulfonylureas or meglitinides: Severe hypoglycemia risk
• IGF-1 LR3 + aggressive carbohydrate restriction: Dangerous
• IGF-1 LR3 in caloric deficit phases: Inefficient — the anabolic signal is wasted if substrate is absent; the hypoglycemia risk is elevated without proper carb intake

Discontinuation triggers at any dose/level:

• Any new or changing skin lesion, lymphadenopathy, or palpable mass
• Symptomatic abdominal distension or early satiety
• Persistent HbA1c elevation despite appropriate carbohydrate management
• New or worsened sleep apnea
• Facial soft-tissue growth suggesting acromegalic changes
• Any cardiovascular symptoms
• Strong family history of cancer that was not previously known at start of use